Rethinking Alzheimer's disease biomarkers: A preliminary look at the brain-kidney connection

The search for accessible Alzheimer's disease biomarkers

Researchers have identified a highly accurate, blood-based diagnostic panel that measures both brain damage and kidney function. Finding reliable Alzheimer's disease biomarkers in blood has historically proved difficult because brain-specific proteins exist in minute concentrations outside the skull.

Currently, the standard diagnostic method relies on cerebrospinal fluid (CSF) extraction. This requires a lumbar puncture, a highly invasive procedure that limits widespread screening.

Doctors desperately need a simple blood test to replace this older method. However, early attempts to measure brain proteins in plasma often yielded inconsistent results, forcing scientists to look beyond the central nervous system.

The brain-kidney connection

A new systematic review and meta-analysis, currently available as a preprint awaiting peer review, evaluated data from 72 studies encompassing nearly 30,000 participants. The researchers measured the diagnostic accuracy of combining plasma neurofilament light chain (NfL)—a marker of nerve damage—with cystatin C, an indicator of kidney function.

The data revealed that patients with the condition exhibited significantly elevated levels of both markers. By integrating these specific proteins with p-tau181, the combined panel achieved an impressive diagnostic accuracy score (AUC) of 0.91.

This suggests that the brain and kidneys share linked physiological mechanisms. When the kidneys fail to clear amyloid proteins efficiently, the resulting systemic stress may accelerate neuronal damage.

What the data cannot confirm yet

Despite these promising figures, this early-stage research leaves several questions unanswered. The meta-analysis relies on retrospective data, meaning it cannot prove whether poor kidney function drives brain deterioration or vice versa.

Furthermore, while the statistical models show high accuracy, the researchers have not yet established standardised clinical cut-off values for these tests. Doctors cannot use these findings to diagnose patients until large-scale, prospective clinical trials validate the exact thresholds required for a positive result.

Moving beyond the central nervous system

If peer review and subsequent trials support these preliminary findings, clinical diagnostics could shift away from the brain as an isolated organ. Future screening protocols might evaluate the following systemic factors:

• Vascular health and peripheral blood flow.
• Systemic inflammation levels across the body.
• Peripheral organ efficiency in clearing toxic proteins.

This multi-organ approach could eventually make early screening as routine as a standard cholesterol check. For now, however, the medical community must wait for the rigorous vetting of the formal peer-review process.